NeoGenomics (NEO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter
April 30, 2019 7:05 AM EDTFT. MYERS, FL / ACCESSWIRE / April 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2019.
First Quarter 2019 Highlights:
Consolidated revenue increased 51% to $95.6 million Clinical Services revenue increased 51% to $86.2 million Pharma Services revenue increased 45% to $9.4 million Gross profit increased 73% to $47.1 millionDouglas M. VanOort, the Company's Chairman and CEO, commented, "We are certainly pleased with our very strong... More
